Key safety and efficacy advantages include:
- Increased drug in tumor due to local injection, enabled by hyaluronan conjugation.
- Increased uptake by cancer cells because cancer CD44 binds hyaluronan.
- Increased drug into local lymph nodes due to normal lymphatic hyaluronan clearance
- Increased drug into local lymph nodes due to drug size in the 20-50 nm lymph node “sweet spot”
- Reduced toxicity due to lower overall dose enabled by high tumor penetration
- Reduced toxicity due to lower peak blood level at any given dose.
Pet Dog with Squamous Cell Cancer Between Nose and Mouth
Large ulcerated locally advanced squamous cell carcinoma:
Complete response after treatment:
Pet Dog with Squamous Cell Cancer in Mouth
|
Squamous Cell Cancer |
 |
Large spontaneous squamous cell cancer presenting as exophytic mass on right lower jaw. |
|
1-Week |
|
Cancer on right lower jaw appears clinically to have significantly receded in 1 week after first HylaPlat injection. |
|
3-Week |
|
Cancer on right lower jaw appears clinically to have resolved further to the point where a formerly occluded tooth is visible at 3 weeks post first HylaPlat injection. Dog has now received 3 rounds of treatment with no evidence of recurrence after 4 months. |
Data and photos from Dr. Jeffrey N. Bryan, DVM, MS, PhD, DACVIM (Oncology), Associate Professor of Oncology & Director,
Comparative Oncology Laboratory, College of Veterinary Medicine, University of Missouri.